As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

We recently compiled a list of the 10 Firms Fall Amid Disappointing Earnings Performance. In this article, we are going to ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other stocks. Ten ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Roberto Bilotti has removed the piece from Galleria Nazionale d’Arte Moderna e Contemporanea in Rome, claiming it was being exhibited in “a dark corner” and was “not valued at all” ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Goldman has recently reduced Moderna Inc (MRNA) stock to Neutral rating, as announced on January 29, 2025, according to Finviz. Earlier, on December 18, 2024, Argus had reduced the stock from a Buy to ...